Annual CFF
$12.19 M
-$23.62 M-65.97%
December 31, 2023
Summary
- As of February 8, 2025, OCX annual cash flow from financing activities is $12.19 million, with the most recent change of -$23.62 million (-65.97%) on December 31, 2023.
- During the last 3 years, OCX annual CFF has fallen by -$10.61 million (-46.55%).
- OCX annual CFF is now -84.45% below its all-time high of $78.36 million, reached on December 31, 2021.
Performance
OCX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$255.00 K
-$10.10 M-102.59%
September 30, 2024
Summary
- As of February 8, 2025, OCX quarterly cash flow from financing activities is -$255.00 thousand, with the most recent change of -$10.10 million (-102.59%) on September 30, 2024.
- Over the past year, OCX quarterly CFF has dropped by -$225.00 thousand (-750.00%).
- OCX quarterly CFF is now -100.36% below its all-time high of $69.87 million, reached on March 31, 2021.
Performance
OCX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$9.56 M
-$225.00 K-2.30%
September 30, 2024
Summary
- As of February 8, 2025, OCX TTM cash flow from financing activities is $9.56 million, with the most recent change of -$225.00 thousand (-2.30%) on September 30, 2024.
- Over the past year, OCX TTM CFF has dropped by -$2.55 million (-21.08%).
- OCX TTM CFF is now -88.76% below its all-time high of $85.11 million, reached on March 31, 2021.
Performance
OCX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
OCX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.0% | -750.0% | -21.1% |
| 3 y3 years | -46.5% | -100.7% | -78.5% |
| 5 y5 years | +0.6% | -100.7% | -78.5% |
OCX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.5% | at low | -100.7% | +51.7% | -87.8% | +17.5% |
| 5 y | 5-year | -84.5% | at low | -100.4% | +51.7% | -88.8% | +17.5% |
| alltime | all time | -84.5% | -100.0% | -100.4% | +56.0% | -88.8% | -100.0% |
OncoCyte Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$255.00 K(-102.6%) | $9.56 M(-2.3%) |
| Jun 2024 | - | $9.85 M(>+9900.0%) | $9.79 M(-19.9%) |
| Mar 2024 | - | $0.00(-100.0%) | $12.21 M(+0.2%) |
| Dec 2023 | $12.19 M(-66.0%) | -$30.00 K(0.0%) | $12.19 M(+0.6%) |
| Sep 2023 | - | -$30.00 K(-100.2%) | $12.12 M(+4.3%) |
| Jun 2023 | - | $12.27 M(<-9900.0%) | $11.62 M(-67.8%) |
| Mar 2023 | - | -$28.00 K(-72.0%) | $36.13 M(+0.9%) |
| Dec 2022 | $35.81 M(-54.3%) | -$100.00 K(-81.1%) | $35.81 M(+0.5%) |
| Sep 2022 | - | -$528.00 K(-101.4%) | $35.64 M(-19.7%) |
| Jun 2022 | - | $36.79 M(<-9900.0%) | $44.38 M(+445.3%) |
| Mar 2022 | - | -$355.00 K(+32.0%) | $8.14 M(-89.6%) |
| Dec 2021 | $78.36 M(+243.7%) | -$269.00 K(-103.3%) | $78.36 M(-4.6%) |
| Sep 2021 | - | $8.21 M(+1401.8%) | $82.13 M(+11.1%) |
| Jun 2021 | - | $547.00 K(-99.2%) | $73.94 M(-13.1%) |
| Mar 2021 | - | $69.87 M(+1900.3%) | $85.11 M(+273.3%) |
| Dec 2020 | $22.80 M(-52.4%) | $3.49 M(>+9900.0%) | $22.80 M(-24.4%) |
| Sep 2020 | - | $28.00 K(-99.8%) | $30.16 M(+1.1%) |
| Jun 2020 | - | $11.71 M(+54.8%) | $29.83 M(+70.1%) |
| Mar 2020 | - | $7.57 M(-30.3%) | $17.54 M(-63.4%) |
| Dec 2019 | $47.87 M | $10.85 M(-3765.5%) | $47.87 M(+30.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$296.00 K(-49.0%) | $36.69 M(-8.3%) |
| Jun 2019 | - | -$580.00 K(-101.5%) | $40.00 M(-5.3%) |
| Mar 2019 | - | $37.89 M(<-9900.0%) | $42.24 M(+248.7%) |
| Dec 2018 | $12.11 M(+21.5%) | -$331.00 K(-111.0%) | $12.11 M(-2.1%) |
| Sep 2018 | - | $3.02 M(+82.3%) | $12.37 M(-18.8%) |
| Jun 2018 | - | $1.66 M(-78.7%) | $15.23 M(+10.7%) |
| Mar 2018 | - | $7.77 M(<-9900.0%) | $13.76 M(+38.0%) |
| Dec 2017 | $9.97 M(+0.9%) | -$74.00 K(-101.3%) | $9.97 M(-1.9%) |
| Sep 2017 | - | $5.88 M(+3166.7%) | $10.16 M(-27.4%) |
| Jun 2017 | - | $180.00 K(-95.5%) | $14.00 M(+1.3%) |
| Mar 2017 | - | $3.98 M(+3163.9%) | $13.82 M(+39.9%) |
| Dec 2016 | $9.88 M(-15.2%) | $122.00 K(-98.7%) | $9.88 M(+1.3%) |
| Sep 2016 | - | $9.72 M(>+9900.0%) | $9.76 M(+16.2%) |
| Jun 2016 | - | $0.00(-100.0%) | $8.39 M(-28.2%) |
| Mar 2016 | - | $42.00 K(-4300.0%) | $11.70 M(+0.4%) |
| Dec 2015 | $11.65 M(>+9900.0%) | -$1000.00(-100.0%) | $11.65 M(-0.0%) |
| Sep 2015 | - | $8.35 M(+153.2%) | $11.65 M(+253.2%) |
| Jun 2015 | - | $3.30 M(>+9900.0%) | $3.30 M(>+9900.0%) |
| Mar 2015 | - | $0.00 | $0.00 |
| Dec 2014 | $0.00 | - | - |
FAQ
- What is OncoCyte annual cash flow from financing activities?
- What is the all time high annual CFF for OncoCyte?
- What is OncoCyte annual CFF year-on-year change?
- What is OncoCyte quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for OncoCyte?
- What is OncoCyte quarterly CFF year-on-year change?
- What is OncoCyte TTM cash flow from financing activities?
- What is the all time high TTM CFF for OncoCyte?
- What is OncoCyte TTM CFF year-on-year change?
What is OncoCyte annual cash flow from financing activities?
The current annual CFF of OCX is $12.19 M
What is the all time high annual CFF for OncoCyte?
OncoCyte all-time high annual cash flow from financing activities is $78.36 M
What is OncoCyte annual CFF year-on-year change?
Over the past year, OCX annual cash flow from financing activities has changed by -$23.62 M (-65.97%)
What is OncoCyte quarterly cash flow from financing activities?
The current quarterly CFF of OCX is -$255.00 K
What is the all time high quarterly CFF for OncoCyte?
OncoCyte all-time high quarterly cash flow from financing activities is $69.87 M
What is OncoCyte quarterly CFF year-on-year change?
Over the past year, OCX quarterly cash flow from financing activities has changed by -$225.00 K (-750.00%)
What is OncoCyte TTM cash flow from financing activities?
The current TTM CFF of OCX is $9.56 M
What is the all time high TTM CFF for OncoCyte?
OncoCyte all-time high TTM cash flow from financing activities is $85.11 M
What is OncoCyte TTM CFF year-on-year change?
Over the past year, OCX TTM cash flow from financing activities has changed by -$2.55 M (-21.08%)